Clal Insurance Enterprises Holdings Ltd Makes New $141.28 Million Investment in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,430,000 shares of the exchange traded fund’s stock, valued at approximately $141,284,000. SPDR S&P Biotech ETF accounts for about 1.2% of Clal Insurance Enterprises Holdings Ltd’s portfolio, making the stock its 23rd largest holding.

Several other institutional investors and hedge funds have also recently modified their holdings of XBI. Nwam LLC acquired a new position in SPDR S&P Biotech ETF in the 3rd quarter valued at about $1,475,000. Biltmore Family Office LLC raised its position in shares of SPDR S&P Biotech ETF by 5.6% during the 3rd quarter. Biltmore Family Office LLC now owns 19,156 shares of the exchange traded fund’s stock valued at $1,893,000 after buying an additional 1,009 shares during the period. Howe & Rusling Inc. acquired a new stake in SPDR S&P Biotech ETF during the third quarter worth $49,000. Tidemark LLC increased its position in shares of SPDR S&P Biotech ETF by 101.5% during the 3rd quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock worth $39,000 after purchasing an additional 199 shares during the last quarter. Finally, Prudent Man Advisors LLC lifted its position in SPDR S&P Biotech ETF by 15.6% in the third quarter. Prudent Man Advisors LLC now owns 13,155 shares of the exchange traded fund’s stock valued at $1,300,000 after buying an additional 1,771 shares during the last quarter.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA:XBI opened at $96.24 on Friday. SPDR S&P Biotech ETF has a fifty-two week low of $71.99 and a fifty-two week high of $105.47. The company has a 50 day moving average price of $98.44 and a 200 day moving average price of $96.23. The stock has a market capitalization of $7.34 billion, a P/E ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.